Tech Company Financing Transactions
Avalyn Pharma Funding Round
Avalyn Pharma, operating out of Seattle, raised $35.5 million from Norwest Venture Partners, F-Prime Capital and Novo Ventures.
Transaction Overview
Company Name
Announced On
4/29/2020
Transaction Type
Venture Equity
Amount
$35,500,000
Round
Series B
Investors
Proceeds Purpose
Additionally, funds will support a Phase I study of AP02, aerosolized nintedanib, a program entering clinical development after successful preclinical studies in two lung injury models.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
701 Pike St. 1500
Seattle, WA 98101
USA
Seattle, WA 98101
USA
Phone
Undisclosed
Website
Email Address
Overview
Avalyn is developing inhaled approaches to treat people with severe respiratory disease. Avalyn is a biopharma company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bruce Montgomery
Chief Scientific Officer
Mark Surber
VP - Finance
Nancy McKinley
VP - Operations
Kelly Otto
VP - Product Management
Stephen Pham
Browse more venture capital transactions:
Prev: 4/29/2020: Qorus venture capital transaction
Next: 4/30/2020: Topia venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs